Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and thank you so much for joining us for Day 2 of the 41st Annual Goldman Sachs Conference -- Healthcare Conference.
And with that, I just wanted to make a couple of disclosures before we start. We are required to make certain disclosures in public appearances about Goldman Sachs' relationships with companies that we discuss. The disclosures relate to investment banking relationships, compensation received or 1% or more ownership.
We are prepared to read aloud disclosures for any issuer upon request. However, these disclosures are available in the most recent reports available to you as clients at our firm portals. Disclosures and updates to these disclosures are also available by ticker on the firm's public website.
In addition, disclosures applicable to research with respect to companies, if any, mentioned herein are available through your investment representative. Further information on the subject companies may be obtained
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |